Results 41 to 50 of about 1,912 (177)

Carbonic Anhydrase Inhibitors in the Treatment of Glaucoma. Review. Part I

Oftalʹmologiâ, 2020
Glaucoma is the main cause of irreversible blindness in the world. Carbonic anhydrase inhibitors (CAIS) used both systemically and topically, reduce intraocular pressure effectively.
N. I. Kurysheva
doaj   +1 more source

Euler and Gourava Sombor Coindices Bounds and Python‐Based QSPR Modeling for Butane Derivatives and Ocular Pharmaceuticals

Journal of Chemistry, Volume 2026, Issue 1, 2026.
Topological indices are crucial in modeling of molecular structures of graphs and are also useful in correlation with physicochemical properties. In this paper, we propose the Euler Sombor coindex and Gourava Sombor coindex, and we derive bounds by using some graph invariants of a graph such as the degree of a vertex, the order, and the size of a graph.
Suha Wazzan, Gul Ozkan Kizilirmak, Munmun Bardhan   +2 more
wiley   +1 more source

Brinzolamide ophthalmic suspension: a review of its pharmacology and use in the treatment of open angle glaucoma and ocular hypertension

Clinical Ophthalmology, 2008
Michele IesterClinica Oculistica, University of Genoa, ItalyAbstract: Brinzolamide is a white powder commercially formulated as a 1% ophthalmic suspension to reduce intraocular pressure (IOP).
Michele Iester
doaj  

Novel Sulfonylhydrazones With Sulfonate Ester Framework: Promising Dual Inhibitors of AChE and hCAs

Biotechnology and Applied Biochemistry, Volume 72, Issue 6, Page 1752-1762, December 2025.
ABSTRACT Alzheimer's disease (AD) is a progressive neurodegenerative disorder that affects millions of individuals worldwide. Treatment strategies for AD vary depending on cognitive and behavioral symptoms, with cholinergic replacement therapy using acetylcholinesterase (AChE) inhibitors being one of the primary approaches.
Cansu Öztürk, Neslihan Balci, Osman Nuri Aslan, Erbay Kalay   +3 more
wiley   +1 more source

Preference for a fixed combination of brinzolamide/timolol versus dorzolamide/ timolol among patients with open-angle glaucoma or ocular hypertension

Clinical Ophthalmology, 2013
Ana Sanseau,1 Juan Sampaolesi,2 Emilio Rintaro Suzuki Jr,3 Joao Franca Lopes,4 Hector Borel51Instituto de la Visión, Ciudad de Buenos Aires, Argentina; 2Consultorio Oftalmologico Sampaolesi, Ciudad de Buenos Aires, Argentina; 3Oftalmoclinica ...
Sanseau A, Sampaolesi J, Suzuki Jr ER, Lopes JF, Borel H   +4 more
doaj  

Clinical Experience with Timolol and Brinzolamide Fixed-combination: A Case Series

Oftalʹmologiâ
One of the approaches to improve the adherence of patients with primary open-angle glaucoma (POAG) to IOP-lowering eye drops therapy is the use of fixed-combinations (FC), since this makes it possible to reduce treatment cost during combined therapy ...
S. V. Yanchenko, Sh. J. Teshaev, S. S. Davlatov, N. Yu. Khuddieva   +3 more
doaj   +1 more source

Evolving Real‐World Data and Evidence Use for New Drugs and Regenerative Medical Products Approvals in Japan—An Analysis of the 6‐Year Trend

Clinical Pharmacology &Therapeutics, Volume 118, Issue 6, Page 1405-1421, December 2025.
Several regulatory initiatives have been made to clarify the acceptability and requirements of real‐world data and real‐world evidence (RWD/E) for the benefit/risk assessment of new medical products in Japan. The objectives of this review were to characterize the use of RWD/E in regulatory applications of new medical products and to describe the ...
Suguru Okami, Kako Shimotsumagari, Yasunari Sadatsuki   +2 more
wiley   +1 more source

The Concise Guide to PHARMACOLOGY 2025/26: Enzymes

British Journal of Pharmacology, Volume 182, Issue S1, Page S307-S403, December 2025.
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander, Doriano Fabbro, Alasdair J. Gibb, Eamonn Kelly, Alistair A. Mathie, Chloe J. Peach, Emma L. Veale, Jane F. Armstrong, Elena Faccenda, Simon D. Harding, Christopher Southan, Jamie A. Davies, Stephanie Annett, Detlev Boison, Kathryn Elisa Burns, Carmen Dessauer, Jürg Gertsch, Nuala Ann Helsby, Angelo A. Izzo, Rennolds Ostrom, Ester Pagano, Andreas Papapetropoulos, Nigel J. Pyne, Susan Pyne, Tracy Robson, Roland Seifert, Johannes‐Peter Stasch, Csaba Szabo, Mario van der Stelt, Albert van der Vliet, Val Watts, Szu Shen Wong   +31 more
wiley   +1 more source

Efficiency, safety, and patient preference of switching from dorzolamide 1%/timolol 0.5% to brinzolamide 1%/timolol 0.5% while maintaining the prostaglandin F2α analog

Clinical Ophthalmology, 2015
Yoshie Shimizu,1 Shunsuke Nakakura,1 Makiko Nishiyama,1 Hitoshi Tabuchi,1 Yoshiaki Kiuchi2 1Department of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, 2Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences ...
Shimizu Y, Nakakura S, Nishiyama M, Tabuchi H, Kiuchi Y   +4 more
doaj  

A comparative study on the efficacy of brinzolamide/timolol versus brinzolamide/brimonidine fixed drug combinations in primary open-angle glaucoma

Future Journal of Pharmaceutical Sciences, 2020
Background To compare the efficacy of brinzolamide 1%/timolol 0.5% fixed drug combination (BTFC) with brinzolamide 1%/brimonidine 0.2% fixed drug combination (BBFC) among the patients with primary open-angle glaucoma (POAG).
Sudeepthi Padala, Ramam Sripada, Srivalli Bhaskari Padmavathi Gundabattula, Krishna Jyothi Tadi, Prabhakar Rao Nallamothula, Farzaneh Raveshi, Dasaratha Dhanaraju Magharla   +6 more
doaj   +1 more source